Noxopharm Ltd
ASX:NOX

Watchlist Manager
Noxopharm Ltd Logo
Noxopharm Ltd
ASX:NOX
Watchlist
Price: 0.097 AUD Market Closed
Market Cap: 28.3m AUD

Operating Margin
Noxopharm Ltd

-190.1%
Current
-181%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-190.1%
=
Operating Profit
-5.4m
/
Revenue
2.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Noxopharm Ltd
ASX:NOX
28.3m AUD
-190%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
402.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
178.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.1B USD
28%
AU
CSL Ltd
ASX:CSL
85.1B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.7B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
No Stocks Found

Noxopharm Ltd
Glance View

Market Cap
28.3m AUD
Industry
Biotechnology

Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).

NOX Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-190.1%
=
Operating Profit
-5.4m
/
Revenue
2.8m
What is the Operating Margin of Noxopharm Ltd?

Based on Noxopharm Ltd's most recent financial statements, the company has Operating Margin of -190.1%.

Back to Top